May 24 (Reuters) - Theratechnologies Inc TH.TO
* Theratechnologies announces that 82.5% of patients
achieved the primary endpoint in the phase III ibalizumab trial
* Says taimed plans to submit an abstract to present these
results at a major scientific conference later this year
Source text for Eikon: ID:nMKWhClwma
Further company coverage: TH.TO
(Bengaluru Newsroom: +1-646-223-8780)